| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.15 | 9e-06 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.32 | 4e-05 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.14 | 8e-05 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.13 | 9e-05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0003 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0007 |